Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study

Glass, BertramBertramGlassHasenkamp, JustinJustinHasenkampGoerlitz, AnkeAnkeGoerlitzDreger, PeterPeterDregerSchubert, JoergJoergSchubertWulf, GeraldGeraldWulfNickelsen, MaikeMaikeNickelsenTruemper, Lorenz H.Lorenz H.TruemperSchmitz, NorbertNorbertSchmitz2018-11-072018-11-072008https://resolver.sub.uni-goettingen.de/purl?gro-2/52925Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Studyconference_abstract000262104702307